



June 12, 2015

## **Xencor to Host R&D Day and Webcast on June 26, 2015**

MONROVIA, Calif., June 12, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that the Company will host a R&D Day on Friday, June 26, 2015, from 8:30 a.m. - 11:30 a.m. ET in New York City.

During the R&D day, members of Xencor's management team will provide updates on its XmAb®5871 and XmAb®7195 development programs and its XmAb®14045 and XmAb® bispecific pipeline.

Guest speakers scheduled to attend and present at the event include:

- **John H. Stone, M.D., M.P.H.**  
Professor of Medicine, Harvard Medical School  
Director, Clinical Rheumatology, Massachusetts General Hospital
- **Tyler Curiel, M.D., M.P.H.**  
Skinner Chair in Cancer Immunotherapy, Professor of Medicine, University of Texas Health Sciences Center San Antonio  
Cancer Therapy and Research Center  
Team Leader, Phase 1 Clinical Trials

### **Webcast Information**

A live audio webcast of the presentation will be available under the "Events & Presentations" section in the Investors section of the Company's website located at <http://investors.xencor.com/events.cfm>. A replay of the presentation will be posted on the Xencor website approximately one hour after the live event and will be available for 30 days following the presentation.

### **About Xencor, Inc.**

Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of asthma and allergic diseases, autoimmune diseases and cancer. Currently, eight candidates that have been engineered with Xencor's XmAb® technology are in clinical development internally and with partners. Xencor's internally-discovered programs include: XmAb5871, which completed a Phase 1b/2a clinical trial for the treatment of rheumatoid arthritis and is in preparation for a clinical trial in IgG4-related disease in 2015; XmAb7195 in Phase 1a development for the treatment of asthma; and XmAb5574/MOR208 which has been licensed to Morphosys AG and is in Phase 2 clinical trials for the treatment of acute lymphoblastic leukemia and non-Hodgkin lymphoma. Xencor's XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action. Xencor partners include Merck, Janssen R&D LLC, Alexion, Novo Nordisk and Boehringer Ingelheim. For more information, please visit [www.xencor.com](http://www.xencor.com).

### **Investor Contact:**

John Kuch, Vice President Finance, Xencor  
Tel: 626-737-8013  
[jkuch@xencor.com](mailto:jkuch@xencor.com)

### **Corporate Communications Contact:**

Jason I. Spark, Canale Communications for Xencor  
Tel: 619-849-6005  
[jason@canalecomm.com](mailto:jason@canalecomm.com)

To view the original version on PR Newswire, visit: <http://www.prnewswire.com/news-releases/xencor-to-host-rd-day-and-webcast-on-june-26-2015-300098180.html>

SOURCE Xencor, Inc.

News Provided by Acquire Media